---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-24-006128"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:23:11.458581+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Haemonetics enters $1B credit agreement; $250M term loan, $750M revolver due 2029

## Summary
- New $250M senior unsecured term loan retires existing term loan under 2022 credit agreement.
- Revolving credit facility increased by $330M to $750M from prior $420M.
- Maturity extended to April 30, 2029, with quarterly amortization increasing over term.
- Interest rate: Adjusted Term SOFR plus spread of 1.125% to 1.750% based on leverage ratio.
- Financial covenants: max leverage 4.00x (4.50x after material acquisition), min interest coverage 3.50x.

## SEC filing metadata
- accession: 0000950103-24-006128
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000095010324006128/0000950103-24-006128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000095010324006128/dp210533_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-24-006128
- JSON: https://secwatch.observer/filing/0000950103-24-006128.json
- Plain text: https://secwatch.observer/filing/0000950103-24-006128.txt

## Key facts
- Debt Financings
  HAEMONETICS CORP incurred credit facility of $250 million senior unsecured term loan with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
  - Instrument: credit facility
  - Principal: $250 million senior unsecured term loan
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent
  - Rate: Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750%
  - Maturity: April 30, 2029
  - Event: incurrence
  source text: The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/313143/000095010324006128/0000950103-24-006128-index.htm
- Debt Financings
  HAEMONETICS CORP incurred revolving credit of $750 million senior unsecured revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent at Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750% maturing April 30, 2029.
  - Instrument: revolving credit
  - Principal: $750 million senior unsecured revolving credit facility
  - Counterparty: JPMorgan Chase Bank, N.A., as administrative agent
  - Rate: Adjusted Term SOFR Rate plus an applicable rate ranging from 1.125% to 1.750%
  - Maturity: April 30, 2029
  - Event: incurrence
  source text: The Revised Credit Agreement provides for a $250 million senior unsecured term loan, the proceeds of which have been used to retire the balance of the term loan under the 2022 Credit Agreement, and a $750 million senior unsecured revolving credit facility, which constitutes a $330 million increase from the revolving credit facility under the 2022 Credit Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/313143/000095010324006128/0000950103-24-006128-index.htm
- Material Agreements
  HAEMONETICS CORP amended Revised Credit Agreement with JPMorgan Chase Bank, N.A. valued at $250 million senior unsecured term loan (effective 2024-04-30).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: JPMorgan Chase Bank, N.A.
  - Value: $250 million senior unsecured term loan
  - Effective: 2024-04-30
  source text: On April 30, 2024, Haemonetics Corporation (the “Company”) entered into a second amended and restated credit agreement by and among the Company, as borrower, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Revised Credit Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/313143/000095010324006128/0000950103-24-006128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.